Back to Search
WENDY RATHMELL, MD
MD
Medical Oncology Physician
NPI: 1477614949Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
35.154722(OH)
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
MD53185(TN)
Research & Publications (20)
Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma.
PMID 19448672·Oncogene·2009
7-preclinical
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.
PMID 19252526·Oncogene·2009
7-preclinical
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.
PMID 19216840·Curr Oncol Rep·2009
6-review
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.
PMID 19061835·Cancer Cell·2008
8-other
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
PMID 18684493·Urology·2008
8-other
High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review.
PMID 18649931·Urology·2008
5-case
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.
PMID 18095884·Expert Rev Anticancer Ther·2008
6-review
von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.
PMID 17992257·J Clin Invest·2007
7-preclinical
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
PMID 17664476·J Clin Oncol·2007
3-trial
Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
PMID 17255303·Clin Cancer Res·2007
6-review
Molecularly targeted therapy in renal cell carcinoma.
PMID 16336094·Expert Rev Anticancer Ther·2005
6-review
In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
PMID 15574766·Cancer Res·2004
7-preclinical
Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer.
PMID 15057147·Am J Clin Oncol·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 2121 KENNY RD FL 5
COLUMBUS, OH 43210 - Phone
- (614) 293-6196
Quick Facts
- NPI
- 1477614949
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile